Managed Care Law Weekly
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Managed Care Law Weekly
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Charles River Laboratories International
Pharma support company updates Q3 outlook, reports softening demand for services
October 9th, 2005
Charles River Laboratories International, Inc., (CRL) said that based upon its current forecast, it expects that for the third quarter ending September 24, 2005, at current exchange rates, its net sales growth and earnings per diluted share will be at the low end, or slightly below, its previous guidance. The company had stated it expected net sales growth to be in a range of 58-61%, earnings per diluted share in a range of $0.44-0.46, and non-generally accepted accounting principles (GAAP) earnings per diluted share in a range of $0.58-0.60. Non-GAAP guidance excludes acquisition-related amortization of intangibles of $13.1 million and compensation charges of $1.3...
Source: Managed Care Law Weekly (2005-10-09)
|
